Literature DB >> 18406309

Endothelins as autocrine regulators of tumor cell growth.

A Bagnato1, K J Catt.   

Abstract

Endothelin 1 (ET-1) is produced by several types of human cancer cells and has been proposed to participate in tumor development or progression by exerting autocrine or paracrine actions on neoplastic cells and their surrounding stromal cells. Recently, an ET-1-mediated autocrine loop has been implicated in the growth of ovarian tumor cells. The co-expression of ET-1 and ET(A) receptors, with consequent activation of growth signaling pathways in human ovarian carcinoma cells, constitutes a mechanism for the autocrine regulation of tumor cell growth. Such findings also provide a basis for further investigation of the role of tyrosine phosphorylation in ET-1-regulated growth responses in ovarian tumor cells. The overexpression of ET-1 and its receptor in cancer cells may serve as a tumor marker, and could provide potential targets for therapy.

Entities:  

Year:  1998        PMID: 18406309     DOI: 10.1016/s1043-2760(98)00094-0

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  21 in total

1.  Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells.

Authors:  Yue Liu; Fei Ye; Kazunari Yamada; Jonathan L Tso; Yibei Zhang; David H Nguyen; Qinghua Dong; Horacio Soto; Jinny Choe; Anna Dembo; Hayley Wheeler; Ascia Eskin; Ingrid Schmid; William H Yong; Paul S Mischel; Timothy F Cloughesy; Harley I Kornblum; Stanley F Nelson; Linda M Liau; Cho-Lea Tso
Journal:  Mol Cancer Res       Date:  2011-10-19       Impact factor: 5.852

2.  Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells.

Authors:  A Bagnato; L Rosanò; V Di Castro; A Albini; D Salani; M Varmi; M R Nicotra; P G Natali
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

Authors:  Snehal G Thakkar; Toni K Choueiri; Jorge A Garcia
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

Review 4.  Endothelin.

Authors:  Yoshifumi Kawanabe; Surya M Nauli
Journal:  Cell Mol Life Sci       Date:  2010-09-17       Impact factor: 9.261

5.  Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor.

Authors:  Bertrand Allard; Anne Wijkhuisen; Aurélie Borrull; Frédérique Deshayes; Fabienne Priam; Patricia Lamourette; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud
Journal:  MAbs       Date:  2012-12-05       Impact factor: 5.857

6.  A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.

Authors:  William R Schelman; Glenn Liu; George Wilding; Thomas Morris; De Phung; Robert Dreicer
Journal:  Invest New Drugs       Date:  2009-09-19       Impact factor: 3.850

7.  Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo.

Authors:  Laura Rosanò; Francesca Spinella; Valeriana Di Castro; Maria Rita Nicotra; Adriana Albini; Pier Giorgio Natali; Anna Bagnato
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

8.  Endothelin (ET)-1 and ET-3 promote expression of c-fos and c-jun in human choriocarcinoma via ET(B) receptor-mediated G(i)- and G(q)-pathways and MAP kinase activation.

Authors:  A Rauh; W Windischhofer; A Kovacevic; T DeVaney; E Huber; M Semlitsch; H-J Leis; W Sattler; E Malle
Journal:  Br J Pharmacol       Date:  2008-03-24       Impact factor: 8.739

Review 9.  ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.

Authors:  Ruth Warren; Glenn Liu
Journal:  Expert Opin Investig Drugs       Date:  2008-08       Impact factor: 6.206

10.  Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer.

Authors:  Frank Wiesmann; Jürgen Veeck; Oliver Galm; Arndt Hartmann; Manel Esteller; Ruth Knüchel; Edgar Dahl
Journal:  Breast Cancer Res       Date:  2009-06-15       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.